Table 4.

Multivariable Cox Regression on Time to Cardiovascular Death, Intention‐to‐Treat Analysis

Variable	Hazard Ratio (95% CI)	P Value
Treatment (cinacalcet/placebo)	0.84 (0.72 to 0.97)	0.019
Age	1.05 (1.04 to 1.05)	<0.001
History of coronary artery disease	1.33 (1.11 to 1.59)	0.002
History of cardiac arrhythmia	1.23 (1.00 to 1.52)	0.051
History of diabetes	1.86 (1.53 to 2.25)	<0.001
History of heart failure	1.22 (1.02 to 1.45)	0.029
History of peripheral vascular disease	1.33 (1.11 to 1.60)	0.002
History of retinopathy	1.15 (0.96 to 1.39)	0.124
History of stroke	1.25 (1.01 to 1.55)	0.044
History of transient ischemic attack	1.26 (0.93 to 1.71)	0.135
Tobacco use (ref, never)		0.003
Current	1.45 (1.17 to 1.81)
Former	1.06 (0.89 to 1.26)
Type of vascular access (ref, natural fistula)		0.071
Permanent catheter	1.18 (0.94 to 1.49)
Graft	1.30 (1.05 to 1.59)
Other	1.23 (0.79 to 1.93)
Baseline statin use	0.85 (0.71 to 1.00)	0.053
Baseline aspirin use	1.02 (0.86 to 1.20)	0.858
Baseline amiodarone use	0.92 (0.62 to 1.39)	0.706
Baseline proton pump inhibitor use	1.14 (0.97 to 1.35)	0.118
Baseline warfarin use	0.95 (0.71 to 1.27)	0.731
Baseline serum phosphorus, mg/dL	1.14 (1.08 to 1.21)	<0.001
Baseline serum albumin, g/dL	0.60 (0.48 to 0.74)	<0.001
Baseline serum total cholesterol, mg/dL	0.99 (0.99 to 1.00)	0.014
Baseline PTH per 100 pg/mL increase	1.02 (1.01 to 1.03)	0.005
Baseline serum LDL per 10 mg/dL increase	1.06 (1.00 to 1.12)	0.057

Variables were selected by backward elimination. The baseline variables vitamin D binder use, hemoglobin level, sex, bone‐specific alkaline phosphatase, and high‐density lipoprotein cholesterol were not included initially due to lack of statistically significant independent association with the end point at α=0.25 in a separate model for each. Baseline use of aspirin, amiodarone, proton pump inhibitor, or warfarin was added to the final model. P=0.047 for interaction of treatment assignment with age. LDL indicates low‐density lipoprotein cholesterol; PTH, parathyroid hormone.